Time New York: Thu 19 Oct 23:22 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Should You Buy Impax Laboratories (IPXL) Ahead of Earnings?

Zacks

Investors are always looking for stocks that are poised to beat at earnings season and Impax Laboratories, Inc. IPXL may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Impax Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for IPXL in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 15 per share for IPXL, compared to a broader Zacks Consensus Estimate of 14 per share. This suggests that analysts have very recently bumped up their estimates for IPXL, giving the stock a Zacks Earnings ESP of +7.14% heading into earnings season.

Impax Laboratories, Inc. Price and Consensus


Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that IPXL has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Impax Laboratories, and that a beat might be in the cards for the upcoming report.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.